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Abstract 
The Cy/+ rat has been characterized as a progressive model of chronic kidney disease-
mineral bone disorder (CKD-MBD). We aimed to determine the effect of kidney disease 
progression on intestinal phosphorus absorption and whole-body phosphorus balance in this 
model. N=48 Cy/+ (CKD) and N=48 normal littermates (NL) rats were studied at two ages: 20-
weeks and 30-weeks, to model progressive kidney function decline at approximately 50 and 20% 
of normal kidney function. Sodium-dependent and sodium-independent intestinal phosphorus 
absorption efficiency were measured by the in situ jejunal ligated loop method using 33P 
radioisotope. Our results show that CKD rats had slightly higher sodium-dependent phosphorus 
absorption compared to NL rats, and absorption decreased from 20- to 30-weeks. These results 
are in contrast to plasma 1,25OH2D, which was lower in CKD rats. Gene expression of the major 
intestinal phosphorus transporter, NaPi-2b, was not different between CKD and NL rats in the 
jejunum but was lower in CKD rats versus NL rats in the duodenum. Jejunal ligated loop 
phosphorus absorption results are consistent with percent net phosphorus absorption results 
obtained from metabolic balance: higher net percent phosphorus absorption values in CKD rats 
compared with NL, and lower values in 30-week-olds compared with 20-week-olds. Phosphorus 
balance was negative (below zero) in CKD rats, significantly lower in 30-week-old rats 
compared with 20-week-old rats, and lower in CKD rats compared with NL rats at both ages. 
These results demonstrate no reduction in intestinal phosphorus absorption with progression of 
CKD despite lower 1,25OH2D status when assessed by an in situ ligated loop test, which is in 
contrast to the majority of in vitro studies, and if confirmed in further studies, could challenge 
the physiological relevance of in vitro findings. 
Keywords: Disorders of calcium/phosphate metabolism, nutrition, genetic animal models, animal 
models, PTH/Vit D/FGF23 
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Introduction 
Chronic kidney disease-mineral bone disorder (CKD-MBD) is characterized by 
biochemical abnormalities related to calcium and phosphorus metabolism, including elevated 
fibroblast growth factor 23 (FGF23), parathyroid hormone (PTH), and serum phosphate, and 
lower serum 1,25-dihydroxyvitamin D3 (1,25D) and calcium, bone abnormalities, and vascular 
or other soft tissue calcification (1). Phosphorus and calcium regulating hormones (FGF23, 
1,25D, PTH) change in early stages of the disease to maintain serum mineral concentrations (2, 
3). However, these hormonal alterations have secondary consequences that contribute to the 
elevated risk for cardiovascular events, bone fragility fractures, and death (4-6). Because 
phosphorus dysregulation is a central driver of these adverse events, interventions aimed at 
maintaining phosphorus homeostasis have been of interest, including targeting the intestinal 
absorption of dietary phosphorus (7). 
Gaps exist in understanding the hormonal regulation of intestinal phosphorus absorption 
in CKD. 1,25D is a recognized positive regulator of the main known intestinal phosphorus 
transporter, sodium phosphate cotransporter-2b (NaPi-2b) and active intestinal phosphorus 
absorption (8). In CKD, 1,25D is decreased via elevated FGF23 (10) and reduced nephron mass 
(9), and therefore active intestinal phosphorus absorption is expected to be lower as kidney 
function declines. However, literature on this topic is mixed. In humans, reduced phosphorus 
absorption has been demonstrated in patients with end-stage kidney disease in older metabolic 
balance studies as well as radioisotope phosphorus tracers (11-13) and in patients on 
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hemodialysis by a triple-lumen perfusion technique (14). These findings have been supported in 
some but not all studies in experimental rat models: Peerce et al. (15) showed decreased sodium-
dependent jejunal brush border membrane vesicle (BBMV) phosphorus uptake in 5/6 
nephrectomized rats versus age-matched controls, and we (16) previously found a reduction in 
active phosphorus transport by Ussing chamber in Cy/+ CKD rats at 21-weeks of age compared 
to normal rats, though this effect appeared to be driven by the groups of rats treated with 
phosphate binders. In contrast, sodium-dependent jejunal BBMV phosphorus uptake was not 
different in 5/6 nephrectomized rats versus sham-operated rats in two additional studies (17, 18). 
Additional assessment techniques that are more physiologic include the in situ ligated 
loop method. Marks et al. (19) also found no difference in 5/6 nephrectomized versus sham-
operated rats using the in situ ligated loop method in the jejunum or duodenum, and gene 
expression of the major intestinal phosphorus transporter, NaPi-2b, was also not downregulated 
with 5/6 nephrectomy. This was despite significantly lower 1,25D levels in the 5/6 
nephrectomized rats. Further, in rats with adenine-induced CKD, the mild-CKD and severe CKD 
rats had similar appearance of 33P into serum over 2 hours after an oral gavage compared with 
controls (20). It is unclear whether differences in these rat experiments are the result of different 
stages of severity of the disease, or methodological differences in the in vitro vs in situ/in vivo 
absorption assessment techniques. This question is important to resolve, because if intestinal 
phosphorus absorption is in fact reduced with CKD, approaches targeting active intestinal 
phosphorus transport may be less effective than anticipated. If intestinal phosphorus absorption 
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is not reduced with disease, then this suggests further complexity than described in current 
models of phosphorus regulation in CKD. 
There are additional unanswered questions in regard to phosphorus homeostasis with 
CKD-MBD progression. Given that changes to tight junction proteins are observed in CKD (21, 
22), and given that paracellular transport of intestinal phosphorus is not well understood, it is 
plausible that sodium-independent absorption could also change with disease progression. To our 
knowledge, only one study has assessed this using BBMV uptake and found no difference in 
sodium-independent phosphorus absorption in 5/6 nephrectomized rats compared to controls 
(18). Additionally, it is unclear whether whole-body phosphorus retention increases with CKD-
MBD progression, as a driver or consequence of disease. Certainly, elevated serum phosphate 
appears in later stages of disease, but serum phosphate does not necessarily reflect whole-body 
status. Human balance studies have shown that moderate-stage CKD patients on average have 
whole-body phosphorus balance around zero (23), but large variability existed with some 
patients having negative, neutral, or positive phosphorus balance (24).  
In this study we aimed to determine the effects of kidney disease progression in the Cy/+ 
rat model of progressive CKD-MBD (25) on intestinal phosphorus absorption as measured by 
the in situ ligated loop absorption method, as well as whole-body phosphorus balance, 
biochemistries of phosphorus and calcium metabolism, and gene expression of the major 
intestinal phosphorus transporters in the jejunum and duodenum. We hypothesized that 
absorption would be similar to controls at a moderate stage of kidney disease but decreased at the 
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later stage, corresponding to a reduction in 1,25D, NaPi-2b expression, and also higher 
phosphorus balance. 
Materials and Methods 
Animals 
Male rats (N = 96) were obtained from the Cy rat colony at the Indiana University School 
of Medicine. Forty-eight heterozygous Cy/+ (CKD) and forty-eight normal Cy +/+ (NL) litter-
mate controls were block randomized using Excel to 20- or 30-week-old age groups in a 2x2 
factorial design (N = 24 rats per age x genotype). Half of the rats in each group were block 
randomized to the sodium-dependent phosphorus absorption test outcome or the sodium-
independent phosphorus absorption test outcome, as these were mutually exclusive procedures. 
Rats were fed standard, unautoclaved rat chow containing 0.7% phosphorus, 1.0% Ca, and 
vitamin D3 1000 IU/kg (Envigo Teklad 2018, Madison, WI) and water ad libitum until 16 weeks 
of age (“baseline”), at which time they were switched to an ad libitum purified casein-based diet 
(0.7% phosphorus and 0.7% calcium, TD.04539, Envigo Teklad, Madison, WI) that has been 
shown to accelerate kidney function decline relative to a grain-based diet likely due to the 
increased phosphorus bioavailability (25), until sacrifice at either 20- or 30-weeks. Rats were 
housed individually in shoe-box cages until five days prior to sacrifice when they were 
transferred to wire-bottom metabolic cages and phosphorus and calcium balance was performed 
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during the last four days prior to sacrifice. Body weights were taken weekly. One rat in the CKD 
30-week group was euthanized due to extreme weight loss from kidney disease prior to reaching 
its assigned age and was not included. One rat assigned to a 30-week group was accidentally 
placed into the metabolic balance period as described below at 20-weeks, therefore its balance 
outcomes were included at both ages. The light-dark cycle was maintained from 6AM-6PM. 
Average room temperature was ~21.5°C (SD 1.0°C) and humidity 46% (SD 7%) This protocol 
was approved by the Purdue University Animal Care and Use Committee. 
 
Intestinal Phosphorus Absorption Efficiency 
Intestinal phosphorus absorption efficiency was determined by in situ jejunal ligated loop 
absorption tests as described previously (26), with the exception of being fasted on the day of 
sacrifice from midnight until morning for the ligated loop absorption test. Half (N = 12) of the 
rats in each age x genotype group were randomly assigned to the “sodium-dependent” absorption 
test using a transport buffer containing (mmol/L): 16 Na-N-2-hydroxyethylpiperazine-N0-2-
ethanesulfonicacid or 4-(2-Hydroxyethyl)piperazin-1-ylethanesulfonic acid, 140 NaCl or ChCl, 
3.5 KCl, 0.1 KH2PO4, and ~5 uCi 33P (33P-orthophosphoric acid, PerkinElmer, Waltham, MA), 
pH 7.4, and the other half (N = 12) to the “sodium-independent” absorption test using a transport 
buffer containing (mmol/L): 4-(2-Hydroxyethyl)piperazin-1-ylethanesulfonic acid, 140 ChCl, 3.5 
KCl, 0.1 KH2PO4, and ~5 uCi 33P, pH 7.4. After injection of the transport buffer (0.5 mL), blood 
(0.5 mL/sampling) was collected at 5, 10, 15, and 30 min post-injection in lithium heparin tubes 
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and centrifuged at 5000 RPM for 10 minutes (Labofuge A 2502, Baxter Scientific Products, 
McGaw Park, IL) to separate plasma. Jejunal loops were removed, the lengths measured, placed 
in a 20 mL scintillation vial containing 6 mL Soluene-350 (Perkin Elmer, Waltham, MA) and 
heated until dissolved (up to 3 days) at 45oC in an oven. After the loop was removed, a final 
blood draw was taken from the jugular catheter for biochemical measures, or by cardiac puncture 
when necessary, and rats were sacrificed by exsanguination followed by cardiac excision.  
Absorption of 33P was evaluated two ways: 1) area under the curve (AUC) was calculated 
for plasma 33P activity over 30 minutes, and 2) percent intestinal phosphorus absorption 
efficiency over 30 minutes was calculated as: 
1 minus (33P activity remaining in digested loop) / (Total 33P activity in 0.5mL dose) X 100  
In addition, because absorption without sodium in the buffer may not be truly sodium-
independent due to endogenous secretions into the intestine (27), an “exclusively” sodium-
dependent component was calculated from each rat as: 
(33P absorption (from loop or AUC)) – (average absorption for the corresponding rat’s group 
given the absorption buffer without sodium)  
The percent sodium-dependency of absorption was calculated as: 
(average absorption for the group given the sodium-containing absorption buffer – average 
absorption for the group given the sodium-free buffer)/(sodium-containing buffer group).  
 
Phosphorus and Calcium Balance and Net Absorption 
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Over the four days prior to sacrifice, urine and feces were collected as previously 
described (26) to assess balance and net absorption of phosphorus and calcium. Feces and diet 
were ashed in a muffle furnace (Thermolyne Sybron Type 30400, Dubuque, IA) for 10 days at 
600oC and diluted 1400X and diet 140X with 2% nitric acid. Urine was diluted 11X with 2% 
nitric acid. Phosphorus and calcium in urine, feces, and diet were quantified by inductively 
coupled plasma-optical emission spectrophotometry (ICP-OES; Optima 4300DV, Perkin Elmer, 
Shelton, CT). Urine creatinine was determined by colorimetric method (Quantichrom, BioAssay 
Systems, Hayward, CA). Four-day phosphorus balance was calculated as dietary phosphorus 
intake (mg/d) – urine and fecal phosphorus excretion (mg/d), and net phosphorus absorption (%) 
as phosphorus intake (mg/d) – fecal excretion (mg/d) / phosphorus intake (mg/d) X 100. Calcium 
balance and net calcium absorption were calculated similarly.  
 
Intestinal Phosphorus Transporter Gene Expression 
After the completion of the ligated loop absorption tests and the removal of the 
radioactive jejunal loop, approximately 8 cm of jejunum distal to the ligated loop and the 
duodenum distal to the pylorus up to the ligated loop were removed and cut open. The mucosal 
layers were scraped, and mucosa from each intestinal segment was placed into TRI Reagent 
(Fisher Scientific, Hampton, NH) and flash frozen in liquid nitrogen for later mRNA 
quantification by RT-PCR. The left kidney was removed, and flash frozen wrapped in foil for 
later mRNA quantification. Upon thawing, kidneys were weighed and cut into thirds cross-
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sectionally. The cortex was removed, mixed thoroughly with a scalpel, and a sample 
homogenized in TRI Reagent (Fisher Scientific, Hampton, NH). 
Gene expression of intestinal NaPi2b and PiT1 using real-time PCR was performed as 
previously described (26). NaPi2a and NaPi2c were assessed in the renal cortex (Applied 
Biosystems Rn00564677_m1 and Rn00595128_m1). 
Plasma Biochemistries 
Plasma stored at -80C was thawed and analyzed for phosphorus, calcium, creatinine, and 
blood urea nitrogen (BUN) concentration by colorimetric methods (phosphorus and calcium: 
Pointe Scientific, Inc., Canton, MI; creatinine and BUN: Quantichrom, BioAssay Systems, 
Hayward, CA). Intact PTH (iPTH) and intact FGF23 (iFGF23) were measured by enzyme-linked 
immunosorbent assay (Alpco, Salem, NH; Quidel, San Diego, CA), and 1,25D by enzyme 
immunoassay (Immunodiagnostic Systems, The Boldons, UK). 
Statistics 
A sample size of n = 12 rats/group was determined to be sufficient to detect a 30% 
difference between groups for phosphorus absorption (β = 0.80, α = 0.05) based on means and 
standard deviations reported by Marks et al. (19). For metabolic balance, biochemical, and gene 
expression outcomes, data from n = 24 rats per disease*age group were analyzed except where 
exceptions are noted. One baseline BUN, one final PTH, and one final FGF23 value were 
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excluded because of implausible values. Baseline biochemistries were not available for all rats, 
and therefore baseline to final changes were not assessed. All outcomes were assessed for 
normality, and creatinine clearance, baseline and final PTH, and gene expression for duodenal 
NaPi-2b and PiT-1, and kidney NaPi-2a and NaPi-2c were log transformed prior to analysis 
because of non-normal distribution of residuals, and reported p-values reflect transformed 
values. Two-way ANOVA was performed for all outcomes with main effects for age and disease 
and their interaction, with Tukey post-hoc comparisons. Linear regression was used to compare 
relationships between absorption and creatinine clearance, BUN, and kidney weight. Statistical 
significance was set at α < 0.05. Statistical Analysis Software version 9.4 (SAS Institute, Cary, 
NC) was used for all two-way ANOVA comparisons, and OriginPro 2018 (OriginLab, 




The baseline blood and urine values at 16 weeks of age between animals randomized to 
the 20- or 30-week age groups are shown in Table 1 and demonstrate similar lab values and 
expected differences between CKD and NL animals. The laboratory tests at the time of sacrifice 
showed evidence of progressive CKD-MBD that was more advanced at 30-weeks compared to 
20-weeks of age. There were no differences in plasma calcium or phosphorus at baseline or final 
draws. Final 1,25D was lower in CKD rats compared to NL and lower in 30-week-olds 
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compared to 20-week-olds. However, Tukey’s post-hoc tests revealed the only difference in 
pairwise comparisons was for 30-week-old CKD rats that had lower 1,25D than all other groups, 
despite a non-significant p = 0.07 for the interaction (Table 2). 
The percent of 33P intestinal phosphorus absorption efficiency, as assessed by 
disappearance of 33P radioactivity from the intestinal loop with the sodium-containing absorption 
buffer at 30 minutes was higher in 20-week-old rats compared with 30-week-olds (35.7 ± 0.9 % 
vs 27.7 ± 1.3 %, p < 0.0001), and higher in CKD rats compared with NL (33.3 ± 1.4 % vs 30.1 ± 
1.3 %, p = 0.04, interaction p = 0.59) (Figure 1). For 33P intestinal absorption efficiency with the 
sodium-free buffer, there was a significant age x disease interaction (p = 0.01), where 20-week 
old CKD and NL rats had higher absorption efficiency than 30-week old NL rats (24.5 ± 1.6 % 
and 27.3 ± 1.5 % vs 18.5 ± 1.3 %, p = 0.02 and p = 0.0003) (Figure 1). Phosphorus absorption 
by plasma AUC had a similar pattern; absorption with the sodium-containing buffer was higher 
in 20-week old rats compared with 30-week-olds (0.7 ± 0.04 vs 0.5 ± 0.03, p < 0.0001), and 
higher in CKD rats compared with NL (0.7 ± 0.03 vs 0.5 ± 0.04, p = 0.001interaction p = 0.68) 
(Figure 2). Similarly, AUC absorption with the sodium-free buffer was higher in 20-week-old 
rats compared with 30-week-old rats (0.5 ± 0.03 vs 0.4 ± 0.02, p = 0.001), and higher in CKD 
compared with NL (0.5 ± 0.03 vs 0.4 ± 0.02, p < 0.0001; interaction p = 0.97) (Figure 2). The 
sodium-dependency of phosphorus absorption varied from 21-35% for CKD rats and 19-33% 
depending on age and method of determination (i.e. label disappearance from loop or appearance 
into plasma) (Supplemental Table 1). There were no strong relationships between absorption 
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outcomes and creatinine clearance, BUN, or kidney weight (all R2 < 0.06, Supplemental Figure 
2). 
Body weight at sacrifice was lower in CKD rats compared with NL and in 20-week-olds 
vs 30-week-olds (Table 2), however body weight was not a significant covariate when tested in 
models for absorption results (all p > 0.08). The mean (SD) of the length of the loops was 5.5 ± 
0.7 cm, and was only a significant covariate (p = 0.04) in the statistical model for phosphorus 
absorption using the sodium-containing buffer, but inclusion as a covariate did not affect the 
results for effects disease or age; length of the loop was not a significant covariate in other 
models for the other outcomes of absorption into plasma or from loops (all p > 0.07). We also 
analyzed absorption buffer pH as a covariate (28) because of an inadvertent error where some 
rats received absorption buffers that had not been pH-adjusted to 7.4 as per protocol. This 
affected N=55/96 rats, ranging from 4 to 10 animals in each group of 12; the difference in pH 
between the sodium-containing vs. sodium-free buffer was 9.4 vs. 5.5. pH was a significant 
covariate in the statistical model for absorption from loops with the sodium-free buffer (p = 0.04) 
but did not change disease and age effects and was not a significant covariate in other models (all 
p > 0.34). Additionally, a subanalysis of rats with only the per protocol buffers with pH adjusted 
to 7.4 (N=41, 2 to 8 per group) yielded similar results for main effects, interactions, and group 
differences as the full set of data reported here.  
Phosphorus and calcium balance and percent net absorption were higher in 20-week-olds 
compared with 30-week-olds (Figure 3 & 4). Phosphorus balance was numerically lower but not 
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statistically significant (p = 0.07), and percent net phosphorus absorption was higher in CKD rats 
versus NL (p = 0.01) (Figures 3A, 4A), but calcium balance and percent net calcium absorption 
were not different between CKD and NL (Figures 3B, 4B). Individual components of 
phosphorus and calcium balance are given in Supplemental Tables 2 and 3. 
NaPi-2b mRNA did not differ by groups in the jejunum, but in the duodenum it was 
lower in CKD rats compared with NL rats, while there was no difference between 20- and 30-
week-olds (Figure 5). There were no effects of age or disease on PiT-1 mRNA in the jejunum, 
but expression was increased at 30-weeks vs 20 in the duodenum (Figure 5). In the kidney, both 
NaPi-2a and NaPi-2c were lower in CKD rats compared with NL, and NaPi-2c was lower at 30-
weeks vs 20-weeks (Figure 5). 
 
Discussion 
 In this study, 20-week-old rats had higher intestinal phosphorus absorption efficiency 
compared with 30-week-old rats as measured by in situ jejunal ligated loop. This corresponds 
with the higher net phosphorus absorption from metabolic balance and greater positive overall 
whole-body phosphorus balance observed in 20-week-old versus 30-week-old rats. Interestingly, 
the results in the NL animals in the present study are in contrast with our previous study in 
healthy Sprague Dawley male rats, in which we observed no age difference in jejunal 
phosphorus absorption efficiency, net phosphorus absorption, nor balance between 20-week-old 
and 30-week-old rats using similar methods (26). This may be due, however, to a difference in 
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rat strain. The Cy rats obtained from the inbred IUSM colony have a Han:Sprague Dawley 
background (29), which may have different physiologic adaptations with age compared to 
commercial Sprague-Dawley rats (Envigo). However, in both studies, the age effects on 
absorption mirrored the age effects on 1,25D: no difference in 1,25D or absorption in 20-week-
old versus 30-week-old Sprague-Dawley rats; higher 1,25D and higher absorption in 20-week-
old versus 30-week-old Cy/+ rats and normal littermates in the present study. This is in 
agreement with the classic understanding of a positive relationship between 1,25D and intestinal 
phosphorus absorption. 
Notably, in CKD rats, intestinal phosphorus absorption efficiency was slightly but 
statistically higher compared with NL, which runs in contrast to the expected effect of lower 
1,25D levels in CKD compared with NL. Similarly, percent net phosphorus absorption from 
metabolic balance was higher in CKD rats versus NL, in line with previous ligated loop 
absorption findings. Marks et al. (30) observed no statistical difference in phosphorus absorption 
using the ligated loop in 5/6 nephrectomized CKD Sprague-Dawley rats in either the jejunum or 
duodenum (but numerically higher in the CKD rats in the jejunum, as in our study), despite 
lower 1,25D in CKD rats. Recently, Turner et al. (20) also showed no difference in phosphorus 
absorption in adenine-induced mild-CKD or advanced CKD compared to controls using an in 
vivo oral gavage method in Sprague-Dawley rats. Our data suggests increased phosphorus 
absorption with CKD in this model, which is unexpected given the low 1,25D levels. Albeit the 
increase is numerically small, and this finding requires replication. Overall, our data show that 
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CKD does not result in a physiological adaptation to limit intestinal phosphorus absorption even 
when 1,25D is low. 
In vitro studies contrast in jejunal brush border membrane vesicle (BBMV) uptake in 5/6 
nephrectomized rats finding either decreased uptake compared with age-matched controls or no 
change compared with sham surgery (17, 18). Interestingly, despite showing a reduction in 
sodium-dependent phosphorus uptake, Peerce et al. found no difference in the percentage of net 
phosphorus absorbed from metabolic balance in CKD rats (15). Further, Marks et al. (30) 
observed no difference in uptake as assessed by the everted gut sac technique in 5/6 
nephrectomized rats compared with sham-operated. In vitro techniques assess uptake into 
enterocytes, whereas the in situ and in vivo assessments include basolateral transport into 
circulation. These methodological differences could illuminate whether basolateral regulation 
can explain different outcomes, although the inconsistencies within in vitro results generally 
rules this out. 
We observed some differences with age between 20- and 30-weeks and between CKD 
and NL when assessing phosphorus transport with a sodium-free absorption buffer, although it is 
unclear whether these reflect true sodium-independent transport with the ligated loop technique. 
Endogenous sodium secretion into the ligated loop during the test may contribute to sodium-
dependent absorption (27). Thus, it is unlikely that we are able to observe true sodium-
independent absorption pathways with this technique compared to completely controlled closed-
system in vitro methods. In support of this, it would be expected that since sodium-dependent 
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absorption is higher in CKD, sodium-independent absorption would be lower consequent to the 
lower phosphate concentration gradient, however this is not consistently observed in our data. 
This is also reflected in the much lower estimations of sodium-dependency when using the 
ligated loop (32±8% in the jejunum) or oral gavage (no evidence of sodium-dependency) (27, 
31) compared to in vitro techniques (73±5% using the everted sleeve) (27) using the same 
phosphate concentration. This may be explained in part by the fact that luminal phosphate 
concentration in vivo is ~1.5-40 mM in the proximal intestine depending on measurement 
technique (27, 32), which would result in a higher proportion of passive transport estimated from 
in vivo compared with in vitro techniques, despite utilizing the same low phosphate 
concentration transport buffer. Our finding of sodium-dependency estimated by appearance into 
plasma in NL rats of 33% is in alignment of the finding of 32% by Marks et al. in healthy 
Sprague Dawley rats using the ligated loop method (27). We also found the same absorption 
patterns (higher in 20-weeks versus 30-weeks and in CKD rats versus NL) when using the 
sodium-free absorption buffer for appearance of 33P into plasma that we observed with the 
sodium-containing buffer. This may reflect a small amount of sodium-dependent transport (due 
to endogenous secretion) in the sodium-free test, although this pattern was not observed for 
absorption when assessed by disappearance of radioactivity from the loop over 30 minutes. A 
previous study found no difference in sodium-independent phosphorus uptake in 5/6th 
nephrectomized CKD rats versus controls in vitro (18); our results contradict this in situ. To 
further explore this question with our data, we calculated an “exclusively” sodium-dependent 
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phosphorus absorption component by subtracting the absorption with the sodium-containing 
buffer for each rat from the absorption average of the corresponding group given the sodium-free 
buffer. This “exclusively” sodium-dependent component was higher in 20-week-old CKD rats 
compared with 20-week NL and 30-week CKD rats for absorption efficiency as measured by 
disappearance from the loop (p = 0.04 and p = 0.02), but not different when assessed as plasma 
AUC (Supplemental Figure 1). By any measure, phosphorous absorption efficiency in CKD 
rats was not lower than NL rats.  
We observed no difference in NaPi-2b mRNA between CKD and NL rats in the jejunum, 
but lower NaPi-2b in CKD rats compared with NL in the duodenum. No CKD differences in 
PiT-1 mRNA were observed in either intestinal segment. Similarly, Marks et al. (19) observed 
no difference in either duodenum nor jejunum NaPi-2b mRNA expression between 5/6th 
nephrectomized compared with sham-operated rats. However, we have previously (16) observed 
lower NaPi-2b mRNA in the duodenum and jejunum, but not ileum, in the same Cy/+ rat model 
compared with NL controls of similar age to the 20-week animals in the present study. 
Interestingly, despite differential changes in NaPi-2b expression, the CKD rats in all three 
studies consistently had 1,25D ~40-50 pg/mL and normal/controls ~≥ 100 pg/mL. It is notable 
that in all studies, the absorption outcomes generally follow NaPi-2b mRNA expression 
outcomes. While we did not measure transporter protein expression, this question is important to 
address in future experiments. Further, although the ligated loop is not ideal to assess sodium-
independent transport, future studies should also examine the modulation of tight junctions, 
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including protein expression therein, with emerging evidence showing changes in response to 
intestinal manipulations that alter phosphate transport such as NaPi-2b knockout (32) and 
sodium/hydrogen exchanger isoform 3 (NHE3) inhibition (33). 
There are several limitations with our model and method. First, the Cy/+ rat is a model of 
autosomal dominant polycystic kidney disease (29), and although the responsible gene mutation 
is known (34), it is unclear if this specific genetic defect can explain our results, although our 
findings are similar to that of Marks et al. (19). Furthermore, we have extensively characterized 
the Cy/+ rat as a model of progressive CKD-MBD, observing biochemical and tissue changes 
similar to the human disease (16, 25). Second, the interpretation of absorption using the ligated 
loop assumes that differences in renal filtration and tissue distribution within the 30 minute 
timeframe of the test will not significantly affect plasma 33P. Recently, Zelt et al. (35) performed 
experiments in nephrectomized rats that address these questions. While kidney filtration was 
only different between pre- and post-nephrectomy beyond a 30-minute period, suggesting that 
this does not affect our interpretation, the nephrectomized group experienced differences in 
tissue distribution 30 minutes post IV infusion of 33P. Their finding of ~75% clearance of 
circulating phosphate within 30 minutes indicates that plasma 33P does not reflect an 
accumulation of absorbed 33P, and this may affect our measurement of absorption into plasma. 
However, a strength of our study is the measurement of absorption by both appearance into 
plasma as well as disappearance from the loop, the latter likely independent of clearance into 
other tissues, which both provided similar results. Third, the inadvertent error of the lack of pH 
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adjustment in some of the absorption buffers would be expected to change our results, but 
inclusion as a covariate and a per protocol sub analysis do not suggest this had a large impact on 
our overall findings; we surmise that the luminal environment may have buffered toward a 
neutral pH with the in vivo test. Candeal et al. (28) showed that total sodium-dependent jejunal 
phosphate BBMV uptake increased as pH decreased from 8.5 to 6, despite decreasing divalent 
phosphate concentrations favored by NaPi-2b. However, Lee et al., using a Ussing chamber, 
showed that phosphate flux decreased from a pH of 6 to 7.4, but increased from 7.4 to 8.5 (36). 
Our pH range of 5.5, 7.4, and 9.4 permit an exploration of this pattern; interestingly, we found 
small but generally consistent absorption patterns that match those of Lee et al. (Supplemental 
Table 4). Both sodium-dependent and -independent transport may be altered by pH (28, 33, 37), 
but it is unclear which is relatively more important in vivo. However, based on the error in pH 
adjustment, our results may be expected to slightly overestimate absorption with both the 
sodium-containing and sodium-free buffer compared to if all rats had been administered the 
correct pH of 7.4. Such differences appear similar to the magnitude of changes in absorption 
between CKD and NL groups, so some caution is needed when considering how this affects 
results. Finally, although our 1,25D measures decreased in the 30-week CKD group consistent 
with other animal studies (16, 19), but without a corresponding decrease in intestinal phosphorus 
absorption, it is possible that a more severe reduction in 1,25D may produce reduced absorption 
using the ligated loop model. In humans, CKD patients with a GFR < 20 ml/min have 1,25D of 
~15 pg/mL, whereas GFR > 80 ml/min were ~ 45 pg/mL (2). It is unclear precisely how 1,25D 
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concentrations in different stages of the human disease relate to those in the rat. However, our 
observations together with Marks et al. (19) of no change or a slight increase in absorption 
efficiency with kidney disease using the ligated loop, versus other studies showing a decrease in 
transport with the Ussing chamber (16), despite similar 1,25D concentrations in diseased rats 
among studies, suggests that methodological differences in how transport is measured may 
explain the different results. 
While patients with end-stage kidney disease (11-13) and on dialysis (14) appear to have 
reduced absorption of dietary phosphorus compared to healthy individuals, whether it is reduced 
in moderate stages of the disease is unresolved. Our results, together with others, suggest that 
absorption is relatively unchanged as the disease progresses to later stages in animal models. 
Thus, interventions that target active intestinal phosphorus transport may be as fruitful as one 
would postulate if human transport parallels rodent models. Although 1,25D decreases markedly 
with disease progression, we observed no reduction in phosphorus absorption, despite the well-
documented effect of 1,25D on increasing absorption via increased NaPi-2b. Future work is 
needed to assess whether a bottom threshold exists for effects of low 1,25D on phosphorus 
absorption in CKD, or if additional regulators are responsible for maintaining phosphorus 
absorption at normal levels in CKD despite declining 1,25D. Our findings further suggest that 
intestinal phosphorus absorption efficiency may even be increased in moderate stages of the 
disease, but this requires additional confirmation. These results underscore the need for further in 
vivo absorption studies in both animal models and clinical research in patients with CKD.  
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Table 1: Baseline blood biochemistries at 16-weeks of age 





NL v. CKD 




n = 20 
6.0 (0.2) 
n = 19 
5.6 (0.2) 
n = 15 
5.8 (0.3) 





n = 20 
6.4 (0.3) 
n = 19 
7.1 (0.4) 
n = 15 
6.1 (0.3) 





















n = 14 
34.1 (0.8) 





n = 17 
444.2 (72.2)  
n = 19 
328.5 (27.0) 
n = 15 
336.8 (18.2) 






n = 15 
745.1 (26.6) 
n = 15 
375.9 (8.2) 
n = 16 
721.1 (24.1) 
n = 15 
<0.0001 
†Baseline blood biochemistries at 16 weeks of age in groups randomized to 20- and 30-week groups. 
ANOVA p-values for the main effect of disease (PDisease) are shown, and means and (SEM) are shown for 
each group. Plasma creatinine was higher in CKD vs NL. Plasma PTH did not differ between groups. 
iFGF23 was higher in CKD rats vs NL. Plasma 1,25D was lower in CKD vs NL.  
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Table 2: Final weights and blood and urine biochemistries† 
 20-weeks-old 30-weeks-old P-Values 
 NL CKD NL CKD ANOVA 
Model  
Age 
(20 vs 30) 
Disease 





487.9 (5.4) b 
n = 24 
460.2 (6.1) c 
n = 24 
546.3 (7.7)a 
n = 24 
511.0 (5.9) b 
n = 23 
< 0.0001 < 0.0001 < 0.0001 0.55 
Kidney 
weight (g) 
1.7 (0.02) c 
n = 22 
2.1 (0.05) b 
n = 22 
1.8 (0.03) c 
n = 24 
2.7 (0.09) a 
n = 23 




n = 22 
6.0 (0.3) 
n = 21 
6.6 (0.4) 
n = 22 
6.2 (0.4) 
n = 21 




n = 22 
5.6 (0.2) 
n = 21 
6.3 (0.2) 
n = 22 
5.7 (0.4) 
n = 21 




0.45 (0.02) c 
n = 23 
0.78 (0.03) b 
n = 23 
0.45 (0.02) c 
n = 23 
0.92 (0.06) a 
n = 22 
<0.0001 0.06 <0.0001 0.056 






14.4 (0.7) bc 
n = 24 
12.3 (0.5) c 
n = 24 
17.4 (0.6) a 
n = 24 
14.8 (0.5) b 
n = 23 




2.55 (0.36) a 
n = 24 
1.18 (0.07) b 
n = 24 
2.85 (0.24) a 
n = 23 
1.35 (0.10) b 
n = 22 
<0.0001 0.08 <0.0001 0.50 
Plasma BUN 
(mg/dL) 
15.0 (0.4) c 
n = 22 
32.3 (0.7) b 
n = 21 
15.7 (0.9) c 
n = 22 
37.0 (1.3) a 
n = 21 
<0.0001 0.003 <0.0001 0.02 
Hematocrit 
(%) 
49.5 (10.1) a 
n = 24 
43.3 (9.2) b 
n = 22 
49.5 (10.1) a 
n = 24 
42.4 (8.8) b 
n = 23 





n = 24 
873.8 (68.0) b 
n = 24 
877.1 (64.8) b 
n = 24 
1849.2 
(239.2) a 
n = 22 






n = 24 
841.0 (49.7) b 
n = 24 
527.0 (24.5) c 
n = 24 
2345.8 
(276.9) a 
n = 22 
<0.0001 <0.0001 <0.0001 <0.0001 








n = 24 
259.2 (36.3) a 
n = 24 
230.5 (37.4) a 
n = 24 
96.1 (22.1) b 
n = 23 
0.0005 0.001 0.02 0.07 
†Final weights, and blood and urine biochemistries. ANOVA p-values for the overall model (PModel), main effect of age (PAge), main effect of 
disease (PDisease), and interaction of age and disease (PAxD) are shown, and means and (SEM) are shown for each group. Different letters represent 
group differences. *average 24 hour urine creatinine (mg/day) over 4-day balance period.
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